Assenagon Asset Management S.A. Has $2.28 Million Stock Position in Inogen, Inc. (NASDAQ:INGN)

Assenagon Asset Management S.A. lowered its stake in Inogen, Inc. (NASDAQ:INGN) by 8.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 234,881 shares of the medical technology company’s stock after selling 20,635 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Inogen were worth $2,278,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Divisadero Street Capital Management LP increased its position in shares of Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after acquiring an additional 2,046,766 shares during the last quarter. Brown Capital Management LLC increased its position in shares of Inogen by 26.6% in the first quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after acquiring an additional 414,903 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Inogen by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock valued at $11,492,000 after acquiring an additional 65,954 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock valued at $4,642,000 after acquiring an additional 129,307 shares during the last quarter. Finally, Meros Investment Management LP grew its holdings in Inogen by 1.6% during the second quarter. Meros Investment Management LP now owns 397,209 shares of the medical technology company’s stock worth $3,229,000 after purchasing an additional 6,385 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Analysts Set New Price Targets

INGN has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.00.

Inogen Stock Down 5.8 %

Shares of NASDAQ:INGN opened at $8.73 on Friday. Inogen, Inc. has a 12-month low of $4.37 and a 12-month high of $13.33. The stock has a market cap of $205.83 million, a PE ratio of -2.09 and a beta of 1.04. The business has a 50 day moving average of $10.40 and a 200-day moving average of $9.29.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.31. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The company had revenue of $88.77 million during the quarter, compared to analysts’ expectations of $82.50 million. During the same quarter in the previous year, the company posted ($0.42) earnings per share. The business’s revenue was up 6.1% on a year-over-year basis. Equities research analysts expect that Inogen, Inc. will post -1.92 earnings per share for the current year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.